Walter Reinisch
Medical University of Vienna
Internal medicineSurgeryRandomized controlled trialIntensive care medicineAdverse effectImmunologyPlaceboAzathioprineInfliximabInflammatory bowel diseaseEndoscopyTofacitinibDiseaseCrohn's diseaseAdalimumabUlcerative colitisIn patientClinical trialMedicineGastroenterology
671Publications
100H-index
33.2kCitations
Publications 735
Newest
#1Neeraj Narula (McMaster University)H-Index: 23
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
view all 7 authors...
Abstract null null Background & Aims null The prognostic value of histologic scores, grades, and individual histologic sub-components, alone or in combination with endoscopy, for predicting endoscopic improvement (EI) and histo-endoscopic mucosal improvement (HEMI) during maintenance therapy in ulcerative colitis (UC) remains uncertain. null null null Methods null Post-hoc analysis of participants from the VARSITY trial (n=734 with histology). Receiver operating characteristic and multi-variate ...
Source
#1Walter Reinisch (Medical University of Vienna)H-Index: 100
Source
#1Eva Untersmayr (Medical University of Vienna)H-Index: 31
#2Elisabeth Förster-Waldl (Medical University of Vienna)H-Index: 19
Last. Wolfram HötzeneckerH-Index: 2
view all 30 authors...
The vaccines against the coronavirus disease 2019 (COVID-19) approved in the European Union represent a decisive step in the fight against the pandemic. The application of these available vaccines to patients with pre-existing immunological conditions leads to a multitude of questions regarding efficacy, side effects and the necessary patient information. This review article provides insight into mechanisms of action of the currently available severe acute respiratory syndrome coronavirus 2 (SAR...
Source
#1Neeraj Narula (McMaster University)H-Index: 23
#2Achuthan Aruljothy (McMaster University)H-Index: 3
Last. Walter Reinisch (Medical University of Vienna)H-Index: 100
view all 7 authors...
This post hoc analysis of the UNITI studies found ustekinumab (UST) did not significantly improve overall extraintestinal manifestations (EIMs) of Crohn's disease compared to placebo-treated patients at weeks 6 and 52. BACKGROUND AND AIMS The UNITI trials demonstrated that UST was effective in inducing and maintaining clinical remission in Crohn's disease (CD). However, limited data exists regarding its effectiveness for treatment of EIMs. This post hoc analysis evaluated the efficacy of UST in ...
2 CitationsSource
#1Manasi Agrawal (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 9
#2Erica J. Brenner (UNC: University of North Carolina at Chapel Hill)H-Index: 6
Last. Michele Kissous-HuntH-Index: 4
view all 14 authors...
The coronavirus disease 2019 (COVID-19) has affected more than 29 million people and led to more than 542,000 deaths in the United States.1 Older age, comorbidities, and racial and ethnic minority status are associated with severe COVID-19.2 Among patients with inflammatory bowel disease (IBD), racial and ethnic minorities have worse outcomes, mediated in part by inequitable health care access.3 Racial and ethnic minority patients with IBD and COVID-19 may be an especially vulnerable population....
Source
#1Parambir S. Dulai (UCSD: University of California, San Diego)H-Index: 29
#2Emily C L Wong (McMaster University)H-Index: 2
Last. Neeraj Narula (McMaster University)H-Index: 23
view all 4 authors...
Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.1-4 We now aim to develop a clinical decision support tool for infliximab in CD.
Source
#1Wong Ecl (McMaster University)
#1Emily C L Wong (McMaster University)H-Index: 2
Last. Neeraj NarulaH-Index: 23
view all 7 authors...
Source
Source
#5John P. Lynch (Janssen Pharmaceutica)H-Index: 27
#5John P. Lynch (Janssen Pharmaceutica)H-Index: 1
Source
Source